Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1391
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 145–156 of 1,391 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Not applicable Interventional

A Pilot Study of a DBT-Informed Caregiver Risk Management Workshop

NCT07852429
Site status not listed — check the official record
View directory record Official record
Conditions
Caregivers, Suicide, Nonsuicidal Self Injury, Adolescent, Young Adult
Interventions
Workshop and consultation for caregivers of at risk youth
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.

NCT07826949
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent High-Grade Gliomas, Brain Neoplasm, Glioma
Interventions
SRN-101, Blood Specimen Collection, Surgical Resection, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Nicholas Butowski
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065
Status at this site: Recruiting
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
54
States / cities
Mesa, Arizona • Sun City, Arizona • Campbell, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

NCT07566052
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Setidegrasib, Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Glendale, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo
Drug
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Other
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264
Site status not listed — check the official record
View directory record Official record
Conditions
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800
Status at this site: Recruiting
View directory record Official record
Conditions
Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions
PF-08634404, Bevacizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
254
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

NCT07458230
Site status not listed — check the official record
View directory record Official record
Conditions
Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
Interventions
NGS diagnostic findings
Diagnostic Test
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606
Status at this site: Recruiting
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

NCT03664609
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor, Dystonia
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Moreno Valley, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 3 Interventional

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380
Status at this site: Recruiting
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions
Vepugratinib, Placebo, EV, Pembrolizumab
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
64
States / cities
Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283
Status at this site: Recruiting
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Brenipatide, Placebo, Buprenorphine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:26 AM EDT

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.